MetaVia Inc. (NASDAQ:MTVA – Free Report) – Equities researchers at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of MetaVia in a research note issued to investors on Monday, March 31st. Zacks Small Cap analyst D. Bautz forecasts that the company will earn ($0.57) per share for the quarter. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share. Zacks Small Cap also issued estimates for MetaVia’s Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.26) EPS, FY2026 earnings at ($1.65) EPS and FY2027 earnings at ($1.53) EPS.
Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of MetaVia in a research report on Friday, March 21st.
MetaVia Price Performance
Shares of NASDAQ MTVA opened at $1.58 on Wednesday. MetaVia has a 12-month low of $1.29 and a 12-month high of $5.30. The firm’s 50 day simple moving average is $1.64.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than MetaVia
- How to Evaluate a Stock Before BuyingÂ
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- The Basics of Support and Resistance
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- Quiet Period Expirations Explained
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
